Cover Image
市場調查報告書

神經診斷市場規模與預測:各技術(神經影像學技術,體外診斷,神經資訊學),市場區隔預測

Neurodiagnostics Market Analysis By Technology (By Neuroimaging Technologies, In Vitro Diagnostics, Neuroinformatics) And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 398905
出版日期 內容資訊 英文 92 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經診斷市場規模與預測:各技術(神經影像學技術,體外診斷,神經資訊學),市場區隔預測 Neurodiagnostics Market Analysis By Technology (By Neuroimaging Technologies, In Vitro Diagnostics, Neuroinformatics) And Segment Forecasts To 2024
出版日期: 2016年11月01日 內容資訊: 英文 92 Pages
簡介

本報告提供神經診斷市場相關調查,市場趨勢與各技術,及各地區預測,競爭趨勢,及加入此市場的主要企業簡介等彙整資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 市場摘要

第4章 市場變數,趨勢,範圍

  • 市場區隔和範圍
    • 促進要素分析
    • 阻礙要素分析
  • 滲透率與成長預測製圖
  • SWOT分析
  • 波特五力分析

第5章 市場類別1:各技術預測與趨勢分析

  • 神經診斷市場
  • 神經影像學技術
    • CT
    • MRI
    • 核醫學
    • 近紅外線光譜分析影像
    • 腦波檢驗
    • 腦磁圖
    • 以體素為基礎的形態計量學(VBM)
  • 體外診斷
  • 神經資訊學

第6章 市場類別2:各地區預測與趨勢分析

  • 各地區趨勢分析
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 競爭環境

  • 企業簡介
    • Agilent Technologies
    • Alpha Omega Ltd.
    • Bruker
    • Doric Lenses, Inc.
    • Fonar Corporation
    • GE Healthcare
    • Guerbet
    • 株式會社日立Medical
    • Hologic, Inc.
    • Mightex Systems
    • NeuroNexus Technologies
    • Neusoft Medical Systems Co., Ltd.
    • Philips Healthcare
    • Plexon, Inc.
    • Plexon, Inc.
    • Roche Diagnostics
    • Siemens Healthcare
    • 東芝MedicalSystems株式會社

圖表

目錄
Product Code: GVR-1-68038-277-8

The global neurodiagnostics market was valued at 13.6 billion in 2015 and is expected to reach a value of USD 18.3 billion by 2024, according to a new report by Grand View Research, Inc. Key factors driving the market growth include increasing prevalence of neurological diseases due to demographic changes and growing awareness of their management. In addition, consistent technological modifications coupled with increased preference for novel diagnostic technologies will further fuel the market. The economic burden of neurological diseases is extremely high on society and governments with around 1 billion people suffering globally.

Among all the neuroimaging techniques, computed tomography has the largest market share followed by Magnetic Resonance Imaging (MRI). Computed Tomography (CT) uses ionized radiations for the purpose of creating images, whereas MRI uses radio waves in a magnetic field. Neuroimaging techniques are used to detect brain injuries, developmental malformations in the brain area, vascular irregularities that may lead to stroke, epilepsy, etc.

Biomarkers are an important part of in vitro diagnostics for neurological disorders as their development is targeted at the early disease diagnosis with information about nervous system. Although biomarkers are not commercially available in the market, their use is confined to clinical research settings. For instance, ELISA tests for Tau protein are available in clinical studies of Alzheimer's disease. In addition, neuroinformatics is a field that studies neuroscience and information technology. This integration allows the storage of neurological data in the form databases. The neuroinformatics market is expected to grow at second highest growth rate during the forecast period.

Further Key Findings From the Study Suggest:

  • Increased life expectancy has resulted in increased geriatric population across the globe. The prevalence of aging-related neurological diseases such as Alzheimer's disease and Parkinson's disease is on the rise. The diagnosis of these diseases includes neuroimaging, in vitro diagnosis, and neuroinformatics.
  • CT and MRI are the most commonly used imaging techniques across the globe, which are mainly used to detect brain abnormalities.
  • Neurological biomarkers are extremely promising as they provide a direction to the diagnostic studies. Although currently no commercial biomarker is available in the market, an extensive clinical research is happening to find out the perfect combinations of the biomarkers.
  • North America held the major market share of around 36% in the year 2015 and will retain its top position during the forecast period. On the other hand, Asia Pacific will exhibit highest CAGR of 4% over the forecast period.

Table of Content

Chapter 1. Methodology & Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Market Summary

Chapter 4. Market Variables, Trends& Scope

  • 4.1. Market Segmentation & Scope
    • 4.1.1. Market driver analysis
    • 4.1.2. Market restraint analysis
  • 4.2. Penetration & Growth Prospect Mapping
  • 4.3. Neurodiagnostics Market-SWOT Analysis, by Factor(Political & Legal, Economic and Technological)
  • 4.4. Industry Analysis-Porter's

Chapter 5. Market Categorization 1: Technology Estimates & Trend Analysis

  • 5.1. Neurodiagnostics Market: Technology Movement Analysis
  • 5.2. Neuroimaging Technologies
    • 5.2.1. Computed tomography(CT)
      • 5.2.2.1. CT market, 2013-2024(USD Million)
    • 5.2.2. Magnetic resonance imaging(MRI)
      • 5.2.2.2. MRI market, 2013-2024(USD Million)
    • 5.2.3. Nuclear medicine imaging(PET, SPECT)
      • 5.2.3.1. Nuclear medicine imaging(PET, SPECT) market, 2013-2024(USD Million)
    • 5.2.4. Near infrared spectroscopic imaging(NIRS)
      • 5.2.4.1. NIRS market, 2013-2024(USD Million)
    • 5.2.5. Electroencephalography(EEG)
      • 5.2.5.1. EEG market, 2013-2024(USD Million)
    • 5.2.6. Magnetoencephalography(MEG)
      • 5.2.6.1. MEG market, 2013-2024(USD Million)
    • 5.2.7. Voxel-based Morphometry(VBM)
      • 5.2.7.1. VBM(VBM) market, 2013-2024(USD Million)
  • 5.3. In Vitro Diagnostics
    • 5.3.1. In vitro diagnostics market, 2013-2024(USD Million)
  • 5.4. Neuroinformatics
    • 5.4.1. Neuroinformatics market, 2013-2024(USD Million)

Chapter 6. Market Categorization 2: Regional Estimates & Trend Analysis, by Technology

  • 6.1. Neurodiagnostics Market Share by Region, 2013 & 2024
  • 6.2. North America
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Europe
    • 6.3.1. UK
    • 6.3.2. Germany
  • 6.4. Asia Pacific
    • 6.4.1. Japan
    • 6.4.2. China
    • 6.4.3. India
  • 6.5. Latin America
    • 6.5.1. Mexico
    • 6.5.2. Brazil
  • 6.6. MEA
    • 6.6.1. South Africa

Chapter 7. Competitive Landscape

  • 7.1. Strategy Framework
  • 7.2. Company Profiles
    • 7.2.1. Agilent Technologies
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Alpha Omega Ltd.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Bruker
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Doric Lenses, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Fonar Corporation
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. GE Healthcare
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Guerbet
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Hitachi Medical Corporation
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Hologic, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Mightex Systems
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. NeuroNexus Technologies
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Neusoft Medical Systems Co., Ltd.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Philips Healthcare
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Plexon, Inc.
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
    • 7.2.15. Plexon, Inc.
      • 7.2.15.1. Company overview
      • 7.2.15.2. Financial performance
      • 7.2.15.3. Product benchmarking
      • 7.2.15.4. Strategic initiatives
    • 7.2.16. Roche Diagnostics
      • 7.2.16.1. Company overview
      • 7.2.16.2. Financial performance
      • 7.2.16.3. Product benchmarking
      • 7.2.16.4. Strategic initiatives
    • 7.2.17. Siemens Healthcare
      • 7.2.17.1. Company overview
      • 7.2.17.2. Financial performance
      • 7.2.17.3. Product benchmarking
      • 7.2.17.4. Strategic initiatives
    • 7.2.18. Toshiba Medical Systems Corporation
      • 7.2.18.1. Company overview
      • 7.2.18.2. Financial performance
      • 7.2.18.3. Product benchmarking
      • 7.2.18.4. Strategic initiatives

List of Tables

  • TABLE 1: Country share estimation
  • TABLE 2: North America neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 3: North America neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 4: U.S. Neurodiagnostics market, by Technology, 2013 - 2024 (USD Million)
  • TABLE 5: U.S. neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 6: Canada neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 7: Canada neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 8: Europe neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 9: Europe neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 10: U.K. neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 11: U.K. neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 12: Germany neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 13: Germany neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 14: Asia Pacific neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 15: Asia Pacific neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 16: Japan neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 17: Japan neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 18: China neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 19: China neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 20: India neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 21: India neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 22: Latin America neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 23: Latin America neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 24: Mexico neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 25: Mexico neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 26: Brazil neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 27: Brazil neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 28: MEA neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 29: MEA neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
  • TABLE 30: South Africa neurodiagnostics market, by technology, 2013 - 2024 (USD Million)
  • TABLE 31: South Africa neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Market summary
  • FIG. 2: Market trends & outlook
  • FIG. 3: Neurodiagnostics: Market segmentation
  • FIG. 4: Market driver relevance analysis (Current & future impact)
  • FIG. 5: Market restraint analysis (Current & future impact)
  • FIG. 6: Penetration & growth prospect mapping
  • FIG. 7: SWOT Analysis, by Factor (Political & legal, economic and technological)
  • FIG. 8: Neurodiagnostics Porter's analysis
  • FIG. 9: Neurodiagnostics market Technology outlook key takeaways
  • FIG. 10: Neurodiagnostics market: Technology movement analysis
  • FIG. 11: Global Neuroimaging Technology market, 2013 - 2024 (USD Million)
  • FIG. 12: Global In Vitro Diagnostics market, 2013 - 2024 (USD Million)
  • FIG. 13: Global Neuroinformatics market, 2013 - 2024 (USD Million)
  • FIG. 14: Neuroimaging Technology market Segments outlook key takeaways
  • FIG 15 : euroimaging Technology: Segments movement analysis
  • FIG. 16: Global computed tomography market, 2013 - 2024 (USD Million)
  • FIG. 17: Global magnetic resonance imaging market, 2013 - 2024 (USD Million)
  • FIG. 18: Global nuclear medicine imaging market, 2013 - 2024 (USD Million)
  • FIG. 19: Global near infrared spectroscopic imaging market, 2013 - 2024 (USD Million)
  • FIG. 20: Global electroencephalography market, 2013 - 2024 (USD Million)
  • FIG. 21: Global magnetoencephalography market, 2013 - 2024 (USD Million)
  • FIG. 22: Global voxel-based morphometry market, 2013 - 2024 (USD Million)
  • FIG. 23: Regional market place: Key takeaways
  • FIG. 24: Regional outlook, 2015 & 2024
  • FIG. 25: Strategy framework
  • FIG. 26: Participant categorization
Back to Top